Education
About Us
Working with TipRanks
Follow Us
Stoke Therapeutics Inc (STOK)
NASDAQ:STOK
Total Valuation
Stoke Therapeutics has a market cap or net worth of $1.30B. The enterprise value is $1.13B.
Market Cap$1.30B
Enterprise Value$1.13B
Share Statistics
Stoke Therapeutics has 57,117,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,117,150
Owned by Insiders38.68%
Owned by Institutions1.64%
Financial Efficiency
Stoke Therapeutics’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -43.35%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-43.35%
Return on Capital Employed (ROCE)-0.44
Revenue Per Employee285.59K
Profits Per Employee-695.16K
Employee Count128
Asset Turnover0.13
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Stoke Therapeutics is 34.0. Stoke Therapeutics’s PEG ratio is 0.22.
PE Ratio34.0
PS Ratio16.30
PB Ratio2.60
Price to Fair Value2.60
Price to FCF-6.84
Price to Operating Cash Flow25.31
PEG Ratio0.22
Income Statement
In the last 12 months, Stoke Therapeutics had revenue of 36.55M and earned -88.98M in profits. Earnings per share was -1.65.
Revenue36.55M
Gross Profit36.55M
Operating Income-101.37M
Pretax Income-88.98M
Net Income-88.98M
EBITDA-99.19M
Earnings Per Share (EPS)-1.65
Cash Flow
In the last 12 months, operating cash flow was 52.85M and capital expenditures -480.00K, giving a free cash flow of 52.37M billion.
Operating Cash Flow52.85M
Free Cash Flow52.37M
Free Cash Flow per Share0.92
Dividends & Yields
Stoke Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.53
52-Week Price Change69.33%
50-Day Moving Average26.40
200-Day Moving Average14.63
Relative Strength Index (RSI)30.45
Average Volume (3m)1.40M
Important Dates
Stoke Therapeutics upcoming earnings date is Mar 11, 2026, Before Open (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateMar 11, 2026
Ex-Dividend Date―
Financial Position
Stoke Therapeutics as a current ratio of 5.81, with Debt / Equity ratio of 0.00%
Current Ratio5.81
Quick Ratio5.81
Debt to Market Cap0.00
Net Debt to EBITDA1.24
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Stoke Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Stoke Therapeutics EV to EBITDA ratio is -4.76, with an EV/FCF ratio of -5.43.
EV to Sales12.93
EV to EBITDA-4.76
EV to Free Cash Flow-5.43
EV to Operating Cash Flow-5.44
Balance Sheet
Stoke Therapeutics has $248.31M in cash and marketable securities with $0.00 in debt, giving a net cash position of $248.31M billion.
Cash & Marketable Securities$248.31M
Total Debt$0.00
Net Cash$248.31M
Net Cash Per Share$4.35
Tangible Book Value Per Share$4.24
Margins
Gross margin is 94.83%, with operating margin of -277.31%, and net profit margin of -243.42%.
Gross Margin94.83%
Operating Margin-277.31%
Pretax Margin-243.42%
Net Profit Margin-243.42%
EBITDA Margin-271.36%
EBIT Margin-277.31%
Analyst Forecast
The average price target for Stoke Therapeutics is $29.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$29.75
Price Target Upside32.40% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast1128.17%
EPS Growth Forecast―